Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC. Patients with advan...

Full description

Bibliographic Details
Main Authors: Connor O’Leary, Harry Gasper, Katherine B. Sahin, Ming Tang, Arutha Kulasinghe, Mark N. Adams, Derek J. Richard, Ken J. O’Byrne
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Pharmaceuticals
Subjects:
non-small-cell lung cancer
epidermal growth factor receptor
EGFR
tyrosine kinase inhibitors
circulating tumor cells
Online Access:https://www.mdpi.com/1424-8247/13/10/273

Internet

https://www.mdpi.com/1424-8247/13/10/273

Similar Items